Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$67.96
3.775.87%
At close: -
$68.25
0.290.43%
After Hours: 4:33 PM EDT
Comments
Loading...
Verona Pharma (NASDAQ:VRNA) Stock, Analyst Ratings, Price Targets, Forecasts
Verona Pharma PLC has a consensus price target of $53.88 based on the ratings of 8 analysts. The high is $74 issued by Wells Fargo on January 8, 2025. The low is $31 issued by BTIG on March 20, 2023. The 3 most-recent analyst ratings were released by Canaccord Genuity, HC Wainwright & Co., and Roth MKM on February 12, 2025, January 21, 2025, and January 10, 2025, respectively. With an average price target of $66.67 between Canaccord Genuity, HC Wainwright & Co., and Roth MKM, there's an implied -2.32% downside for Verona Pharma PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
HC Wainwright & Co.
Roth MKM
Wells Fargo
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Verona Pharma
Data brought to you by Benzinga APIs
FAQ
What is the target price for Verona Pharma (VRNA) stock?
The latest price target for Verona Pharma (NASDAQ:VRNA) was reported by Canaccord Genuity on February 12, 2025. The analyst firm set a price target for $72.00 expecting VRNA to rise to within 12 months (a possible 5.49% upside). 23 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verona Pharma (VRNA)?
The latest analyst rating for Verona Pharma (NASDAQ:VRNA) was provided by Canaccord Genuity, and Verona Pharma maintained their buy rating.
When was the last upgrade for Verona Pharma (VRNA)?
There is no last upgrade for Verona Pharma
When was the last downgrade for Verona Pharma (VRNA)?
There is no last downgrade for Verona Pharma.
When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on February 12, 2025 so you should expect the next rating to be made available sometime around February 12, 2026.
Is the Analyst Rating Verona Pharma (VRNA) correct?
While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a maintained with a price target of $44.00 to $72.00. The current price Verona Pharma (VRNA) is trading at is $68.25, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.